GHRP-6 & CJC-1295 MIX 10mg/vial 1 Vial by Bio-Peptide

Usage

1. Calculate your target dose based on appetite tolerance: users new to GHRP-6 should begin at 100 mcg because the hunger effect is pronounced — experienced GHRP-2 users transitioning to this blend should expect a noticeably stronger appetite signal.
2. Reconstitute the 10 mg lyophilized vial with 2 mL of bacteriostatic water (yielding 5 mg/mL) by injecting the water slowly down the inside wall of the vial — never inject directly onto the powder cake.
3. Swirl gently — do not shake — until the powder dissolves completely; a clear, colourless solution indicates full reconstitution.
4. Draw the required volume into a U-100 insulin syringe; at 5 mg/mL, a 100 mcg dose equals 0.02 mL and a 250 mcg dose equals 0.05 mL.
5. Inject subcutaneously into the abdominal or deltoid region on an empty stomach (or at least 2 hours post-meal) to maximise GH pulse amplitude — then eat within 30 minutes to harness GHRP-6's appetite window for a productive anabolic meal.
6. Refrigerate the reconstituted vial at 2–8 °C immediately after use; label with the reconstitution date and discard after 28 days regardless of remaining volume.

Warnings

Frequently asked questions

Which GHRP causes more hunger — GHRP-6 or GHRP-2?

GHRP-6 causes significantly more hunger than GHRP-2. Both peptides bind GHS-R1a and stimulate GH release, but GHRP-6 activates hypothalamic NPY/AgRP appetite pathways far more potently, producing moderate-to-strong hunger in most users. GHRP-2 generates only a mild appetite response at equivalent GH-releasing doses, making GHRP-6 the clear choice for individuals who want appetite stimulation alongside GH secretion.

Who benefits most from the appetite-stimulating side effect of GHRP-6?

Athletes in a mass-building or caloric surplus phase benefit most from GHRP-6's appetite effect. Users who struggle to hit high daily calorie targets — hard gainers, people with fast metabolisms, or those recovering from illness-related appetite loss — find that GHRP-6's hunger drive supports dietary compliance. Conversely, individuals in a cutting phase may prefer GHRP-2 specifically because its appetite stimulation is negligible.

How does GH output compare between GHRP-6 and GHRP-2 at the same dose?

GH output is broadly comparable between GHRP-6 and GHRP-2 at equivalent microgram doses, with GHRP-2 sometimes showing a marginally higher peak GH pulse in research settings. However, that GH advantage is modest and largely offset when either peptide is co-administered with a GHRH analogue like CJC-1295, which amplifies both pulses significantly. The more meaningful clinical difference between the two lies in appetite stimulation, not peak GH magnitude.

How do you reconstitute and store a 10 mg GHRP-6 vial, and what syringe should be used?

Reconstitute the 10 mg lyophilized vial with bacteriostatic water — typically 2 mL for a concentration of 5 mg/mL, allowing precise insulin-syringe dosing in small increments. Use a standard U-100 insulin syringe for subcutaneous injection. After reconstitution, store the vial upright in a refrigerator at 2–8 °C; discard unused solution within 28 days. Never freeze a reconstituted vial, as this degrades peptide integrity.

Why is the 10 mg/vial concentration of this GHRP-6 blend advantageous over lower-dose formats?

At 10 mg per vial, this Bio-Peptide blend provides the highest concentration available in its product group, delivering more research doses per vial and reducing reconstitution frequency. A single vial at 5 mg/mL reconstitution yields roughly 40 individual 250 mcg doses, offering extended-use value. Higher concentration also allows flexible dilution ratios, giving researchers precise control over per-injection volume — an important consideration when using insulin syringes. (2) angle_used

Manufacturer

Bio-Peptide's entry into the peptide research market was shaped by a founding commitment that preceded any commercial scaling decision: no vial would carry the company's label without an independent laboratory confirming both its sequence identity via HPLC and its endotoxin safety via LAL testing. That policy was not a response to regulatory pressure — it preceded formal sector scrutiny and reflected the founders' view that unverified purity claims had become structurally endemic in the European research-compound space. Each certificate of analysis produced under this framework is batch-specific, tied to a unique lot identifier, and reviewable rather than genericised. Manufacturing operations align with cGMP principles across the full production arc: raw amino-acid sourcing, synthesis, lyophilisation, and final vial preparation each fall within documented quality checkpoints. The result is a brand whose reputation within the research community rests on procedural consistency rather than marketing positioning — a distinction that becomes particularly relevant for complex blended products like the GHRP-6 & CJC-1295 MIX, where sequence fidelity of two active peptides must be confirmed independently.